Suprachoroidal Injection of Triamcinolone Acetonide With... | NCT02980874

NCT02980874

Status Module

Oversight Module

Description Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Active	Experimental	IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections	Drug: suprachoroidal CLS-TA Drug: IVT aflibercept
Control	Active Comparator	IVT aflibercept (2 mg/0.05 mL) + sham SC procedure	Drug: suprachoroidal sham Drug: IVT aflibercept

Name	Type	Description	Arm Group Labels	Other Names
suprachoroidal CLS-TA	Drug	suprachoroidal injection of CLS-TA	Active

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)	Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.	2 months

Secondary Outcomes

Measure	Description	Time Frame
Mean Change From Baseline in Best Corrected Visual Acuity	Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.

Eligibility Module

Contacts/Locations Module

Name	Affiliation	Role
Thomas Ciulla, MD MBA	Clearside Biomedical, Inc.	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Associated Retina Consultants, Ltd.		Peoria	Arizona	85381	United States
Retinal Consultants of Arizona and Retinal Research Institute

IPD Sharing Statement Module

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Active	IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections suprachoroidal CLS-TA: suprachoroidal injection of CLS-TA IVT aflibercept: 2 mg intravitreal injection of aflibercept
FG001	Control

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Document Section

Large Document Module

Uploaded Document Information

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot_SAP	Yes	Yes	No	Study Protocol and Statistical Analysis Plan	Mar 31, 2017

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

IVT aflibercept (2 mg/0.05 mL) + sham SC procedure

suprachoroidal sham: suprachoroidal sham procedure

IVT aflibercept: 2 mg intravitreal injection of aflibercept

Arm/Group Information

ID	Title	Description
BG000	Active	IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections suprachoroidal CLS-TA: suprachoroidal injection of CLS-TA IVT aflibercept: 2 mg intravitreal injection of aflibercept
BG001	Control	IVT aflibercept (2 mg/0.05 mL) + sham SC procedure suprachoroidal sham: suprachoroidal sham procedure IVT aflibercept: 2 mg intravitreal injection of aflibercept
BG002	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Categorical

Age of patients in years relative to the date of the Screening visit.

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
<=18 years	BG0000 BG0010 BG0020
Between 18 and 65 years

Age, Continuous

Age of patients in years relative to the date of the Screening visit.

Mean

Standard Deviation

Years

Title

Denominators

Categories

Title	Measurements
	BG00066.4± 12.31 BG00164.9± 12.42

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG00097 BG001105 BG002

Race (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG0002 BG0010 BG002

Region of Enrollment

Count of Participants

Participants

Title

Denominators

Categories

Hungary

Title	Measurements
	BG0006 BG0011 BG002

Type of Retinal Vein Occlusion

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Branch retinal vein occlusion	BG000124 BG001124 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)

Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.

The Intent-to-treat population included all randomized subjects who received at least one study treatment.

Posted

Count of Participants

Participants

2 months

ID	Title	Description
OG000	Active	IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections suprachoroidal CLS-TA: suprachoroidal injection of CLS-TA IVT aflibercept: 2 mg intravitreal injection of aflibercept
OG001	Control	IVT aflibercept (2 mg/0.05 mL) + sham SC procedure suprachoroidal sham: suprachoroidal sham procedure IVT aflibercept: 2 mg intravitreal injection of aflibercept

Units	Counts
Participants	OG000231 OG001229

Title

Denominators

Categories

Title	Measurements
	OG000114 OG001127

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001	Based on a Pearson chi-square test, a total sample size of approximately 460 subjects provided 90% power to detect a difference of 15% between the Active and Control arms assuming the Control arm showed a proportion of 0.50 at 8 weeks. The primary analysis was a test of superiority of the Active arm over the Control arm, and was based on a Cochran-Mantel-Haenszel chi-square test stratified by type of retinal vein occlusion.	Cochran-Mantel-Haenszel	The CMH test was stratified by the type of retinal vein occlusion, i.e., branch vs. central.	0.187	The a priori threshold for statistical significance was 0.050. Prior to evaluating the results of the CMH test, a Breslow-Day test with Tarone's adjustment was conducted to confirm the homogeneity of the odds ratios between RVO strata.	Difference in percentages	-6.1			2-Sided	95	-15.2	3.0

Secondary

Mean Change From Baseline in Best Corrected Visual Acuity

Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.

The Intent-to-treat population included all randomized subjects who received at least one study treatment.

Posted

Least Squares Mean

Standard Error

Letters

6 months

ID	Title	Description
OG000	Active	IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections suprachoroidal CLS-TA: suprachoroidal injection of CLS-TA IVT aflibercept: 2 mg intravitreal injection of aflibercept
OG001	Control	IVT aflibercept (2 mg/0.05 mL) + sham SC procedure suprachoroidal sham: suprachoroidal sham procedure IVT aflibercept: 2 mg intravitreal injection of aflibercept

Units	Counts
Participants

Secondary

Mean Change From Baseline in Central Subfield Thickness

Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.

The Intent-to-treat population included all randomized subjects who received at least one study treatment.

Posted

Least Squares Mean

Standard Error

Microns

6 months

ID	Title	Description
OG000	Active	IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections suprachoroidal CLS-TA: suprachoroidal injection of CLS-TA IVT aflibercept: 2 mg intravitreal injection of aflibercept
OG001	Control	IVT aflibercept (2 mg/0.05 mL) + sham SC procedure suprachoroidal sham: suprachoroidal sham procedure IVT aflibercept: 2 mg intravitreal injection of aflibercept

Units	Counts
Participants

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Active	IVT aflibercept (2 mg/0.05 mL) + CLS-TA (4 mg/100 µL) SC injections suprachoroidal CLS-TA: suprachoroidal injection of CLS-TA IVT aflibercept: 2 mg intravitreal injection of aflibercept	0	231	25	231	128	231
EG001	Control	IVT aflibercept (2 mg/0.05 mL) + sham SC procedure suprachoroidal sham: suprachoroidal sham procedure IVT aflibercept: 2 mg intravitreal injection of aflibercept	0	229	28	229	83	229

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Notes	Statistical Information
Anaemia	Blood and lymphatic system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0013 events3 affected229 at risk
Acute coronary syndrome	Cardiac disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Atrial fibrillation	Cardiac disorders	MedDRA (19.0)	Non-systematic Assessment		EG0002 events2 affected231 at risk EG0011 events1 affected229 at risk
Coronary artery disease	Cardiac disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0012 events2 affected229 at risk
Myocardial infarction	Cardiac disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0012 events2 affected229 at risk
Cataract	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	#Fellow eye	EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Retinal detachment	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	#Study eye	EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Ulcerative keratitis	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	#Study eye	EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Visual acuity reduced	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	#Study eye	EG0002 events2 affected231 at risk EG0010 events0 affected229 at risk
Vitreous haemorrhage	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	#Study eye	EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Gastritis	Gastrointestinal disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Intestinal obstruction	Gastrointestinal disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Large intestinal obstruction	Gastrointestinal disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Pancreatitis acute	Gastrointestinal disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Abasia	General disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Chest pain	General disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0012 events2 affected229 at risk
Pyrexia	General disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Appendicitis perforated	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Bronchitis	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Colonic abscess	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Diverticulitis	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Empyema	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Endophthalmitis	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment	#Study eye	EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Hepatitis C	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Perirectal abscess	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Pneumonia	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Pyelonephritis	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Urinary tract infection	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment		EG0002 events2 affected231 at risk EG0010 events0 affected229 at risk
Alcohol poisoning	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Facial bones fracture	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Fall	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Head injury	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Multiple fractures	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Pelvic fracture	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Rib fracture	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Road traffic accident	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Spinal fracture	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Sternal fracture	Injury, poisoning and procedural complications	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Intraocular pressure increased	Investigations	MedDRA (19.0)	Non-systematic Assessment	#Study eye	EG0003 events3 affected231 at risk EG0010 events0 affected229 at risk
Dehydration	Metabolism and nutrition disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Hyponatraemia	Metabolism and nutrition disorders	MedDRA (19.0)	Non-systematic Assessment		EG0002 events2 affected231 at risk EG0010 events0 affected229 at risk
Lactic acidosis	Metabolism and nutrition disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Rotor cuff syndrome	Musculoskeletal and connective tissue disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0012 events1 affected229 at risk
Ovarian cancer metastatic	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Paraganglion neoplasm malignant	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Squamous cell carcinoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Balance disorder	Nervous system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Cerebrovascular accident	Nervous system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0011 events1 affected229 at risk
Coma	Nervous system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Dizziness	Nervous system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0011 events1 affected229 at risk
Facial paralysis	Nervous system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Hemiplegia	Nervous system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Syncope	Nervous system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0002 events2 affected231 at risk EG0010 events0 affected229 at risk
Transient global amnesia	Nervous system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Transient ischaemic attack	Nervous system disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0013 events3 affected229 at risk
Major depression	Psychiatric disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Mental status changes	Psychiatric disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Acute kidney injury	Renal and urinary disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0011 events1 affected229 at risk
Haematuria	Renal and urinary disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Benign prostatic hyperplasia	Reproductive system and breast disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Pelvic pain	Reproductive system and breast disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Prostatomegaly	Reproductive system and breast disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0011 events1 affected229 at risk
Lung disorder	Respiratory, thoracic and mediastinal disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Pulmonary congestion	Respiratory, thoracic and mediastinal disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Aortic arteriosclerosis	Vascular disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk
Aortic stenosis	Vascular disorders	MedDRA (19.0)	Non-systematic Assessment		EG0000 events0 affected231 at risk EG0011 events1 affected229 at risk
Hypertension	Vascular disorders	MedDRA (19.0)	Non-systematic Assessment		EG0001 events1 affected231 at risk EG0010 events0 affected229 at risk

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Cataract	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	EG00029 events21 affected231 at risk EG00112 events9 affected229 at risk
Cataract subcapsular	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	EG00022 events20 affected231 at risk EG0013 events3 affected229 at risk
Conjunctival haemorrhage	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	EG00065 events42 affected231 at risk EG00131 events28 affected229 at risk
Eye pain	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	EG00024 events20 affected231 at risk EG00111 events11 affected229 at risk
Macular oedema	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	EG00011 events8 affected231 at risk EG00116 events13 affected229 at risk
Visual acuity reduced	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	EG00018 events16 affected231 at risk EG0017 events6 affected229 at risk
Vitreous detachment	Eye disorders	MedDRA (19.0)	Non-systematic Assessment	EG00016 events13 affected231 at risk EG00110 events9 affected229 at risk
Intraocular pressure increased	Investigations	MedDRA (19.0)	Non-systematic Assessment	EG00051 events33 affected231 at risk EG00113 events9 affected229 at risk
Nasopharyngitis	Infections and infestations	MedDRA (19.0)	Non-systematic Assessment	EG0009 events9 affected231 at risk EG00113 events13 affected229 at risk
Hypertension	Vascular disorders	MedDRA (19.0)	Non-systematic Assessment	EG00018 events15 affected231 at risk EG00117 events15 affected229 at risk

Certain Agreements

ID	Term
D008268	Macular Degeneration
D012162	Retinal Degeneration
D012164	Retinal Diseases
D005128	Eye Diseases
D020246	Venous Thrombosis
D013927	Thrombosis
D016769	Embolism and Thrombosis
D014652	Vascular Diseases
D002318	Cardiovascular Diseases

ID	Term
D014221	Triamcinolone
D011245	Pregnadienes
D011278	Pregnanes
D013256	Steroids
D000072473	Fused-Ring Compounds
D011083	Polycyclic Compounds
D013259	Steroids, Fluorinated